Status:
COMPLETED
Beneficial Effects of Long Term Menaquinone-7
Lead Sponsor:
Maastricht University Medical Center
Conditions:
Bone Loss
Arteriosclerosis
Eligibility:
FEMALE
55-65 years
Phase:
NA
Brief Summary
From all K-vitamins, menaquinone-7 (MK-7) has been identified now as the most effective cofactor for the carboxylation reaction of Gla-proteins such as osteocalcin (in bone) and matrix-Gla protein (in...
Eligibility Criteria
Inclusion
- Healthy postmenopausal women between 55 and 65 years old
- Subjects of normal body weight and height according to BMI \< 30
- Subjects of Caucasian race
- Subject has given written consent to take part in the study
Exclusion
- Subjects with (a history of) metabolic or gastrointestinal disease
- Subjects presenting chronic degenerative and/or inflammatory disease
- Subjects receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters
- Subjects receiving corticoϊd treatment
- Subjects using oral anticoagulants
- Subject using bisphosphonates
- Subjects using hormone replacement therapy
- Subjects undergoing ovariectomy and/or hysterectomy
- Subject with (a history of) soy allergy
- Subjects using vitamin K containing multivitamins or vitamin K supplements
- Subjects who have participated in a clinical study more recently than one month before the current study
- Subjects who are found to be osteoporotic at baseline (T-score \< -2.5)
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00642551
Start Date
March 1 2008
End Date
September 1 2011
Last Update
June 12 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VitaK BV / Maastricht University
Maastricht, PO Box 616, Netherlands, 6200 MD